Jianyong Li
0000-0002-9931-4055
Publication & Citation Trends
Most Cited Works
Publications
1,066 total
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial PDF
Cited by 265
OpenAlex
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia PDF
Cited by 261
OpenAlex
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma PDF
Cited by 400
OpenAlex
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? PDF
Cited by 290
OpenAlex
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia PDF
Cited by 1,543
OpenAlex
A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value PDF
Cited by 305
OpenAlex
Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial
Cited by 178
OpenAlex
Research Topics
Chronic Lymphocytic Leukemia Research
(341)
Lymphoma Diagnosis and Treatment
(326)
Acute Myeloid Leukemia Research
(167)
Chronic Myeloid Leukemia Treatments
(112)
Multiple Myeloma Research and Treatments
(103)
Frequent Co-Authors
Affiliations
Shanghai University
Jiangsu University
Chongqing Normal University
Pennsylvania State University
Union Hospital